Bioventus Inc. (NYSE:BVS) CFO Sells $113,018.49 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 10,733 shares of Bioventus stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $113,018.49. Following the sale, the chief financial officer now owns 105,162 shares in the company, valued at approximately $1,107,355.86. This trade represents a 9.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bioventus Price Performance

Shares of Bioventus stock opened at $10.62 on Friday. The stock has a market capitalization of $861.87 million, a price-to-earnings ratio of -17.41 and a beta of 0.79. The firm’s 50-day moving average price is $11.81 and its two-hundred day moving average price is $9.82. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38.

Bioventus (NYSE:BVS) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The business had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. During the same period in the prior year, the company earned $0.05 EPS. On average, equities analysts predict that Bioventus Inc. will post 0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Canaccord Genuity Group raised their price target on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Craig Hallum boosted their price target on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, September 27th. Finally, JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BVS. Bank of New York Mellon Corp acquired a new stake in Bioventus in the 2nd quarter valued at about $647,000. HB Wealth Management LLC acquired a new stake in shares of Bioventus in the second quarter valued at approximately $60,000. Panagora Asset Management Inc. bought a new position in Bioventus in the 2nd quarter worth approximately $787,000. Rhumbline Advisers lifted its holdings in Bioventus by 5,367.9% during the 2nd quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock worth $302,000 after buying an additional 51,478 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in Bioventus by 403.1% in the 2nd quarter. Acadian Asset Management LLC now owns 27,956 shares of the company’s stock valued at $159,000 after buying an additional 22,399 shares during the last quarter. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.